Heron (Shanghai) Pharma and Nikkol obtained the First Excipients CDMF Number for Medium Chain Triglycerides
April 15th, 2021, Nikkol Triester-F810 of Japan Nikko Chemicals Co., Ltd., was awarded with the excipient CDMF registration number of National Medical Products Administration: H20210000084. Heron Pharma is the exclusive China Mainland distributor of Nikkol Chemical in pharmaceutical and veterinary industry, and this is the first CDMF number we got as the first step and initiating milestone in excipients field.
Basic product information
- USP Name: Medium-Chain Triglycerides
- Usage: This product has excellent solubility, lubricity, oxidation stability, cooling stability, and low viscosity. Good hydrophilism, it can be quickly dispersed in the body to the body fluid, and can be quickly and completely removed in the blood.
Product introduction
This product is a triglyceride mixture obtained by esterification of octanoic acid, capric acid and other saturated fatty acids separated from the fatty oil extracted from the hard dry part of coconut endosperm or the dry part of oil palm endosperm with glycerol. Compared with long-chain fatty acid triglycerides (LCT), MCT has lower melting point and smaller molecular structure. It is liquid at room temperature. Different physical and chemical properties lead to faster and more efficient digestion and absorption of MCT in vivo than LCT, which will not lead to fat accumulation in vivo. It may also reduce intestinal injury and protect liver from toxicity.
NiKKO GROUP was founded in 1946, which is a leading Japanese chemical company with over 70 years of history. Its products have been widely recognized in the fields of daily chemical and medicine. Heron (Shanghai) Pharmaceutical Science and Technology Co., Ltd. is a subsidiary of Heron Pharmaceutical, which is responsible for the marketing and sales of API and feed additives. Heron Pharmaceutical was established in 2013, which is an innovative pharmaceutical enterprise specializing in the R & D and industrialization of innovative drugs and the first generic drugs in China. The company successively obtained the manufacture license of pharmaceutical products and the accreditation certificate of foreign drug manufacturer by Japan PMDA in 2018.
Post time: Apr-19-2021